Drugs / Gentulizumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05221385 | Apr 2021 → May 2023 | non-Hodgkin lymphoma | Changchun GeneScience Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05263271 | Apr 2021 → Dec 2024 | acute myeloid leukemia, myelodysplastic syndrome | Changchun GeneScience Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gentulizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05221385 ↗ |
| Action | Inhibit | “an antibody that inhibits an anti-apoptotic signal in human macrophages” NCT05221385 ↗ |
| Modality | Monoclonal antibody | “an Anti-CD47 Monoclonal Antibody” NCT05221385 ↗ |
| Route | Intravenous | “Gentulizumab is administered IV once a week” NCT05221385 ↗ |
| Target | CD47 | “Anti-CD47” NCT05221385 ↗ |